Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer

被引：0
|
作者：
Julia Foldi
Anastasia Tsagianni
Max Salganik
Catherine A. Schnabel
Adam Brufsky
G. J. van Londen
Lajos Pusztai
Tara Sanft
机构：
[1] Yale School of Medicine,Section of Medical Oncology
[2] University of Pittsburgh School of Medicine,Division of Hematology and Medical Oncology
[3] Biotheranostics Inc,undefined
[4] A Hologic Company,undefined
来源：
BMC Cancer | / 23卷
关键词：
Breast Cancer Index; Extended adjuvant endocrine therapy; Endocrine therapy adherence;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Use and Effectiveness of Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer in Men
    Venigalla, Sriram
    Carmona, Ruben
    Guttmann, David M.
    Jain, Varsha
    Freedman, Gary M.
    Clark, Amy S.
    Shabason, Jacob E.
    JAMA ONCOLOGY, 2018, 4 (10)
  • [42] Adjuvant Systemic Therapy for Postmenopausal, Hormone Receptor-Positive Early Breast Cancer
    Johnston, Stephen R. D.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (01) : 89 - 102
  • [43] Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer
    Tevaarwerk, Amye J.
    Wisinski, Kari B.
    O'Regan, Ruth M.
    JOURNAL OF ONCOLOGY PRACTICE, 2016, 12 (11) : 1148 - +
  • [44] Updates in Systemic Treatment of Hormone Receptor-Positive Early-Stage Breast Cancer
    Hsu, Emily
    Arezo, Sabrina M.
    Graff, Stephanie L.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2024, 25 (10) : 1323 - 1334
  • [45] In It for the Long Haul: Long-Term Benefit With Adjuvant Endocrine Therapy for Premenopausal Women With Early-Stage Steroid Receptor-Positive Breast Cancer
    Davidson, Nancy. E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (35) : 4037 - +
  • [46] Role of adjuvant endocrine therapy in early-stage breast cancer
    Muss, HB
    SEMINARS IN ONCOLOGY, 2001, 28 (04) : 313 - 321
  • [47] Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR plus breast cancer in the TEAM trial
    Bartlett, J. M.
    Xu, K.
    Wong, J.
    Pond, G.
    Zhang, Y.
    Spears, M.
    Salunga, R.
    Mallon, E.
    Taylor, K. J.
    Hasenburg, A.
    Markopoulos, C.
    Dirix, L. Y.
    Seynaeve, C.
    van de Velde, C.
    Rea, D.
    Schnabel, C. A.
    Treuner, K.
    Bayani, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S602 - S602
  • [48] Information for decision making by post-menopausal women with hormone receptor positive early-stage breast cancer considering adjuvant endocrine therapy
    Feldman-Stewart, Deb
    Madarnas, Yolanda
    Mates, Mihaela
    Tong, Christine
    Grunfeld, Eva
    Verma, Shailendra
    Carolan, Hannah
    Brundage, Michael
    BREAST, 2013, 22 (05): : 919 - 925
  • [49] Quality of life in women with early-stage and metastatic hormone receptor-positive, HER2-negative breast cancer receiving endocrine therapy
    O'Reilly, David
    Farooq, Abdul Rehman
    Selvadurai, Paul Nevins
    Sheehan, Laura
    Molan, Karen
    Krishnanivas, Bindu
    Mullen, Valerie
    Mcmahon, David
    Hadi, Danial
    Ahmed, Ahmed
    Jennings, Maeve
    Carroll, Hailey
    Chew, Sonya
    Macanovic, Bojan
    Brown, Ciara O'Hanlon
    Noonan, Sinead A.
    Reilly, Seamus O.
    Connolly, Roisin M.
    Cahir, Caitriona
    Kelly, Catherine M.
    ONCOLOGIST, 2024, 29 (10): : 842 - 849
  • [50] Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer
    Delea, Thomas E.
    Karnon, Jon
    Sofrygin, Oleg
    Thomas, Simu K.
    Papo, Natalie L.
    Barghout, Victoria
    CLINICAL BREAST CANCER, 2007, 7 (08) : 608 - 618
12345